{"title": "PDF", "author": "PDF", "url": "www.mountsinai.org/files/MSHealth/Assets/MSH/April-Community-Newsletter.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "APRIL 2021Our Community\nMount Sinai Health System\nCOVID-19 Vaccines Offer the Protection We Need\ncontinued \u203aMore than 90 million doses \nof the COVID-19 vaccine \nhad been administered \nnationwide at the beginning \nof March. According to the \nCenters for Disease Control \nand Prevention (CDC), these \nvaccines have undergone \nthe most intensive safety \nmonitoring in United States \nhistory. Studies show the \nvaccines are effective at \nkeeping you from getting \nCOVID-19\u2014and may also help \nyou avoid getting seriously  \nill if you do become infected. \nSeveral new variants of  \nSARS-CoV-2, the virus that \ncauses COVID-19, have been \ndetected within the United \nStates since the vaccine rollout \nbegan in December, raising \nconcerns about the nation\u2019s \nability to return to normality \nin 2021. Chief among these \nconcerns is whether the \nnational effort to vaccinate as \nmany Americans as possible\u2014\nand as quickly as possible\u2014\nwill be able to offset the virus\u2019s \nenhanced ability to spread. \nAt the heart of that question \nlies another: Will the vaccines \nfrom Moderna and Pfizer/\nBioNTech, along with the \nthird from Johnson & Johnson \n(J&J), recently approved \nby the U.S. Food and Drug \nAdministration (FDA), offer Mount Sinai Medical Center  |  Brand Guidelines  3Color is the primary visual device we \nuse to build consistent recognition of \nour brand. \nColor applications\nThe preferred version is our four-color \nlogo on a white background. The logo \nmay NOT appear on dark-colored \nbackgrounds. Please see the color \nbackgrounds page for more details.\nOne color applications\nThe logo may also be reproduced in \nsolid black on white.\nPantone\u00ae  \nProcess  \nCyan \nC  100   \nM 0   \nY  0   \nK 0\nR 0   \nG 174  \nB 239Pantone\u00ae  \n233\nC 10  \nM 100   \nY 0   \nK 0\nR 216   \nG 11  \nB 140Pantone\u00ae  \nProcess  \n274\nC 100   \nM 100 \nY 0   \nK 28\nR 34   \nG 31  \nB 114Pantone\u00ae  \nProcess  \nBlack\nC 0   \nM 0   \nY 0   \nK 100\nR 0   \nG 0  \nB 0Logo color applications\n4 Color  logo on white \nPrimary color palette1 Color logo on white\nQ: Will these variants \nprevent us from beating  \nthis pandemic? \nA: We suspect there will \nbe more variants and we \nwill have to deal with them. \nViruses want to live and \nthey keep reproducing and \nmutating\u2014whether it is the \nhuman immunodeficiency \nvirus (HIV), which causes \nAIDS, or the influenza virus, \nwhich develops different \nstrains. Every year when we \nget the flu vaccine there is \nstill a chance we will get the \nflu, but the vaccine probably \nprevents us from developing \na severe case.\nWith SARS-CoV-2, which \ncauses COVID-19, you \nhave multiple variants \nthat are circulating in the \nU.S. and globally during \nthis pandemic. Until we \nhave more data on vaccine \ndurability and efficacy \nagainst the variants we are \ngoing to have to do what  \nwe are doing now. \nVaccinated individuals  \nshould continue to follow \nsafe practices but can feel \nsome reassurance. For those \nwho are not yet vaccinated, \ndo not delay in getting \nwhichever vaccine becomes \navailable to you.adequate protection against \nthese new variants? Mount \nSinai\u2019s infectious diseases \nexperts answer these \nimportant questions.\nJudith A. Aberg, MD, Dean \nof System Operations for \nClinical Sciences, and Chief \nof the Division of Infectious \nDiseases, at the Icahn School \nof Medicine at Mount Sinai \nleads the Mount Sinai Health \nSystem\u2019s COVID-19 treatment \nand vaccine clinical trial \nefforts. Dana Mazo, MD, \nMSc, Assistant Professor of \nMedicine (Infectious Diseases) \nat the Icahn School of \nMedicine at Mount Sinai and \nHospital Epidemiologist at \nMount Sinai Queens, is also the \nlead investigator of the Mount \nSinai Queens COVID-19 clinical trials unit, which is a J&J \nCOVID-19 vaccine trial site.\nQ: Do the vaccines from \nModerna and Pfizer protect \nus from the new variants?\nA: At this time, no one has \nsufficient data to provide \nus with a definitive answer. \nWe have indications from \nboth Moderna and Pfizer \nthat their vaccines produce \nenough effective antibodies \nto overcome the variants, \nbut people may still become \nmildly ill from the variants \nalthough not severely ill. \nPfizer and Moderna both \nannounced that a third booster \ndose targeting the COVID-19 \nvariants may be needed, should \nthe strains prove resistant to \nthe existing vaccines.\nTHE MOUNT SINAI HEALTH SYSTEM \u2022 COMMUNITY AND GOVERNMENT AFFAIRS \u2022 ONE GUSTAVE L. LEVY PLACE, BOX 1037 NEW YORK, NY 10029 \u2022 LINDA.HACKETT@MOUNTSINAI.ORG \u2022 646-265-1754 THE MOUNT SINAI HEALTH SYSTEM \u2022 COMMUNITY AND GOVERNMENT AFFAIRS \u2022 ONE GUSTAVE L. LEVY PLACE, BOX 1037 NEW YORK, NY 10029 \u2022 LINDA.HACKETT@MOUNTSINAI.ORG \u2022 646-265-1754continued\nQ: Is it okay to mix \nvaccines for the first and \nsecond doses or take more \nthan one vaccine?\nA: Do not mix vaccines. \nFinish two doses of the same \nvaccine, or take J&J\u2019s single \ndose. We do not know if the \nantibody response you get \nto one vaccine will impair \nyour immune response to the \nother vaccine. Even though \nModerna and Pfizer vaccines \nare based on the same mRNA \ntechnology, they are still \ndifferent vaccines.\nQ: How effective is the \nnew vaccine from Johnson  \n& Johnson?\nA: Across all regions studied, \nthe vaccine was 85 percent \neffective in preventing severe \ndisease. Additionally, no one \nwho received the vaccine \nneeded to be hospitalized \nand there were no deaths \nrelated to COVID-19. In the \nUnited States, the vaccine \nhad an efficacy of 72 percent \nagainst moderate and severe \nCOVID-19, which is really \nimpressive. That means that \npeople who received the \nvaccine were 72 percent less \nlikely to get moderate or \nsevere disease.\nThe Moderna vaccine is 94 \npercent effective at preventing \nsymptomatic COVID-19, and \nthe Pfizer vaccine is 95 percent \neffective. Experts said the \nthree vaccines should not be \ncompared based on those \nnumbers alone, because they \nall provide strong protection \nagainst severe disease.Mount Sinai Medical Center  |  Brand Guidelines  3Color is the primary visual device we \nuse to build consistent recognition of \nour brand. \nColor applications\nThe preferred version is our four-color \nlogo on a white background. The logo \nmay NOT appear on dark-colored \nbackgrounds. Please see the color \nbackgrounds page for more details.\nOne color applications\nThe logo may also be reproduced in \nsolid black on white.\nPantone\u00ae  \nProcess  \nCyan \nC  100   \nM 0   \nY  0   \nK 0\nR 0   \nG 174  \nB 239Pantone\u00ae  \n233\nC 10  \nM 100   \nY 0   \nK 0\nR 216   \nG 11  \nB 140Pantone\u00ae  \nProcess  \n274\nC 100   \nM 100 \nY 0   \nK 28\nR 34   \nG 31  \nB 114Pantone\u00ae  \nProcess  \nBlack\nC 0   \nM 0   \nY 0   \nK 100\nR 0   \nG 0  \nB 0Logo color applications\n4 Color  logo on white \nPrimary color palette1 Color logo on white\ntaking part in a trial of an \ninvestigational vaccine and \nconsented to participate \nknowing that they would either \nreceive an injection of placebo \n(salt water) or the J&J vaccine. \nParticipants were asked twice \na week if they had symptoms, \nand if anyone reported \nsymptoms, they were tested  \nto see if they had COVID-19. \nQ: What is your advice for \nindividuals who have been \nfully vaccinated?\nA: These vaccines are a \nvery important part of our \nprevention toolbox. We \ncannot rely on just one \nthing. We do not want to set \nexpectations that you are \nnot going to get COVID-19, \nbut the vaccines decrease \nyour chances of getting really \nsick or being hospitalized. So \nuntil the virus is under better \ncontrol and we no longer see \nsuch a high incidence rate, \nwe still need to be careful \nby wearing a mask and \ncontinuing to social distance. Q: How does this vaccine \ncompare with the other two \nvaccines? Is it better?\nA: Each of the vaccines has \npros and cons. The fact that \nthe J&J vaccine is one single \ndose is a real benefit because \nit allows more people to get \nfull protection. This vaccine is \nalso much easier to store and \ntransport. Some of the other \nvaccines require ultra-cold \nstorage, which is not possible \nin many places. \nWith the J&J single-dose \nvaccine, you may also have a \nlower risk of side effects, as \nopposed to two doses which \npresent two opportunities \nfor side effects. From the \ndata already released, the \nJ&J vaccine seems very well \ntolerated. Only 9 percent of \npeople reported fever after \nvaccination and 0.2 percent \nreported fevers bad enough to \ninterfere with daily activities.\nQ: Does it matter which \nvaccine I get?\nA: Get the first vaccine  \nthat is offered to you. All  \nof the vaccines offer \ngood protection against \nsevere COVID-19 disease, \nhospitalization, and death.\nQ: You were involved in \nthe clinical trial. What did \nMount Sinai do and why is \nthat important?\nA: At Mount Sinai Brooklyn \nand Mount Sinai Queens, we \nrecruited members of our \nmost diverse neighborhoods \nwho were interested in Q: Some reports say \nJohnson & Johnson\u2019s \nvaccine is less effective \nthan others. Is that true, \nand is that important? \nA: This is an important \nquestion. One of the \ndifferences with the J&J \nvaccine is that the trial was \nmore recent, and the data \nreleased is from the winter of \n2020. At that time we were \nseeing more COVID-19 cases \nand new variants. Looking \nat other countries, the J&J \nvaccine had lower efficacy \nin South America of 66 \npercent and South Africa of \n57 percent, and the overall \nefficacy around the world  \nwas 66 percent.\nThe trial, conducted in eight \ncountries across three \ncontinents, includes a diverse \nand broad population including \n34 percent of participants over \nage 60. The study enrolled  \n44 percent of participants in \nthe United States: 74 percent \nof trial participants identified \nas White/Caucasian; 15 percent \nas Hispanic and/or Latinx, \n13 percent as Black/African \nAmerican, 6 percent  \nas Asian and 1 percent as \nNative American.\nAnother key aspect of the  \nJ&J vaccine is that it is \nonly one single dose. Other \nvaccines have released higher \nefficacy data at 90 percent \nor more, but after two doses. \nThis is a huge benefit and \nhas the potential to be a real \ngame changer in our fight \nagainst the pandemic.Get the latest \nCOVID-19 \nvaccination \ninformation from \nMount Sinai\nPlease visit  \nwww.mountsinai.org/\nabout/covid19/vaccine-\ninformation  for the most \ncurrent information on  \nthe availability, use,  \neffectiveness, and timing  \nof these vaccines. Get the first vaccine that is offered to you. All of \nthe vaccines offer good protection against severe \nCOVID-19 disease, hospitalizations, and deaths.\u203a \u203a\n \nAPRIL 2021\nMount Sinai Medical Center  |  Brand Guidelines  3Color is the primary visual device we \nuse to build consistent recognition of \nour brand. \nColor applications\nThe preferred version is our four-color \nlogo on a white background. The logo \nmay NOT appear on dark-colored \nbackgrounds. Please see the color \nbackgrounds page for more details.\nOne color applications\nThe logo may also be reproduced in \nsolid black on white.\nPantone\u00ae  \nProcess  \nCyan \nC  100   \nM 0   \nY  0   \nK 0\nR 0   \nG 174  \nB 239Pantone\u00ae  \n233\nC 10  \nM 100   \nY 0   \nK 0\nR 216   \nG 11  \nB 140Pantone\u00ae  \nProcess  \n274\nC 100   \nM 100 \nY 0   \nK 28\nR 34   \nG 31  \nB 114Pantone\u00ae  \nProcess  \nBlack\nC 0   \nM 0   \nY 0   \nK 100\nR 0   \nG 0  \nB 0Logo color applications\n4 Color  logo on white \nPrimary color palette1 Color logo on white\nCommunity Virtual  Events\nMount Sinai Health System\nTuesdays, April 6 & 20\n4 \u2013 5 pm\nDIABETES CLASSES AT MOUNT SINAI\nThese sessions will alternate between the Diabetes \nEducation and the Diabetes Action Group. You do \nnot have to attend every class, however you will \nbe more informed if you participate in all of the \ngroup\u2019s sessions. A Certified Diabetes Educator \nconducts classes.\nJoin Zoom Meeting:  \nFor more information and to RSVP, email  \nCamilla Levister at Camilla.Levister@mssm.edu .\nSPONSORED BY: Mount Sinai Diabetes Center Thursdays, April 8, 15, 22 & 29 \n11 am \u2013 Noon\nWOMAN TO WOMAN: GYNECOLOGIC \nCANCER GROUP\nMeet other women who have been diagnosed with \nthis life-changing disease and have the opportunity \nto share your story. The goal is to decrease \nisolation, share resources, help you feel empowered, \nand have you learn ways to cope with the ups and \ndowns this diagnosis brings. We will be joined by \nguest speakers who are specialists in their fields.\nJoin Zoom Meeting: \nhttp://bit.ly/3sI7bhY\nMeeting ID:  841 7354 5693 \nCall in:  929-205-6099\nMeeting ID:  84173545693#\nSPONSORED BY:  Cancer Supportive Services\nMondays, April 12 & 26 \n1 \u2013 2 pm\nRADIATION SUPPORT GROUP\nThis is a space for people who have had or  \nare currently receiving radiation treatments.\nFor more information, or to RSVP, email  \nEmily Szafara at emily.szafara@mountsinai.org   \nor call 212-523-7541, or Eric White at  \neric.white@mountsinai.org  or call 212-844-6072. \nJoin Zoom Meeting:  \nhttps://bit.ly/37OCzo0 \nMeeting ID:  320 489 3433\nCall in:  1-646-876-9923\nSPONSORED BY: Cancer Supportive Services  Tuesday, April 13  \nNoon \u2013 1 pm\nWOMAN TO WOMAN: LIVING WITH \nRECURRENT GYNECOLOGIC CANCER\nThis group is for survivors of gynecologic \ncancer who have experienced a recurrence. \nGain support, learn from others, and share \nresources with those who have faced cancer \na second time.\nJoin Zoom Meeting:  \nhttp://bit.ly/3b7HgdK  \nMeeting ID:  827 5694 9116 \nCall in: 929-205-6099\nMeeting ID:  82756949116#\nSPONSORED BY: Cancer Supportive Services The Mount Sinai Health System will \ncontinue to offer Virtual Events ,  \nwhich take place remotely and allow \nyou to connect online with a phone, \nlaptop, desktop, or tablet. Please \nuse the links, dial-in numbers, and \nmeeting IDs below to join us!\nABC\u2019s of  \nCancer Clinical Trials \nHOW THEY CAN HELP YOU\nRegistration is required. \nJoin Zoom Meeting:  \nFor Zoom information and to RSVP,  \nplease email cssevents@mountsinai.org   \nor call 212-523-7541.\nSPONSORED BY: Cancer Supportive ServicesSpanish Workshop\nWednesday, April 21 \nNoon \u2013 1 pm\nPanelists:\nNicholas Rohs, MD, Assistant Professor of \nMedicine (Hematology and Medical Oncology)\nIvonne Pereira, NP, Mount Sinai West\nMaria T. Estrella, Co-Director of LatinaSHARE\nModerator:\nAlyssa Freeman, LMSW\nChinese/Mandarin Workshop\nFriday, April 23\n11 am \u2013 Noon\nPanelists:\nTheresa Shao, MD, Assistant Professor of \nMedicine (Hematology and Medical Oncology)\nHing Lin (Helen) Sit, LCSW, Manager of \nChinatown NORC, Visiting Nurse Service  \nof New York\nModerator:\nMi (Emma) Zhou, LCSW, Social Work Supervisor\nEnglish Workshop\nThursday, April 29 \nNoon \u2013 1 pm\nPanelists:\nStephanie Blank, MD, Director of Gynecologic \nOncology, Mount Sinai Health System\nDana Dornsife, the Founder and CEO of \nLazarex Cancer Foundation\nModerator:\nEmily Szafara, Social Work Intern\nTHE MOUNT SINAI HEALTH SYSTEM \u2022 COMMUNITY AND GOVERNMENT AFFAIRS \u2022 ONE GUSTAVE L. LEVY PLACE, BOX 1037 NEW YORK, NY 10029 \u2022 LINDA.HACKETT@MOUNTSINAI.ORG \u2022 646-265-1754Las vacunas contra el COVID-19 ofrecen  \nla protecci\u00f3n que necesitamos\nM\u00e1s de 90 millones de dosis de \nla vacuna contra el COVID-19 \nhan sido administradas a trav\u00e9s \nde todo el pa\u00eds durante los \nprimeros d\u00edas de marzo. Seg\u00fan \nlos Centros para el Control y \nPrevenci\u00f3n de Enfermedades \n(CDC, por sus siglas en ingl\u00e9s), \nestas vacunas han sido \nsometidas al monitoreo de \nseguridad m\u00e1s intenso en la \nhistoria de los Estados Unidos. \nLos estudios demuestran que \nlas vacunas son eficaces para \nevitar que usted se infecte con \nel COVID-19 y tambi\u00e9n pueden \nayudar a evitar que se enferme \ngravemente si se infecta. \nVarias de las nuevas variantes \ndel SARS-CoV-2, el virus \nque causa el COVID-19, se \nhan detectado dentro de los \nEstados Unidos desde que \ncomenz\u00f3 la implementaci\u00f3n de \nla vacuna en diciembre, lo que \nplantea preocupaciones sobre \nla capacidad de la naci\u00f3n para \nvolver a la normalidad en el \n2021. La principal preocupaci\u00f3n \nes si el esfuerzo nacional para \nvacunar al mayor n\u00famero \nde estadounidenses\u2014y lo \nantes posible\u2014ser\u00e1 capaz de \ncompensar la mayor capacidad \nde propagaci\u00f3n del virus. \nEn el centro de esa pregunta \nse encuentra otra: \u00bfLas \nvacunas de Moderna y Pfizer/\nBioNTech, junto con la tercera \nde Johnson & Johnson (J&J), \nrecientemente aprobadas \npor la Administraci\u00f3n de \ndirigida a las variantes \ncovid-19, en caso de que las \nvariantes resulten resistentes  \na las vacunas existentes.\nP: \u00bfNos impedir\u00e1n estas \nvariantes vencer esta \npandemia?\nR: Sospechamos que habr\u00e1 \nm\u00e1s variantes y tendremos que \nlidiar con ellas. Los virus quieren \nvivir y siguen reproduci\u00e9ndose \ny mutando, ya sea el virus  \nde inmunodeficiencia humana \n(VIH), que causa el SIDA o \nel virus de la gripe, el que \ndesarrolla diferentes variantes. \nCada a\u00f1o, cuando nos \nvacunamos contra la gripe \nexiste la posibilidad de que  \nnos enfermemos, pero la \nvacuna probablemente ayuda  \na que no sea un caso grave.\nCon EL SARS-CoV-2, que causa \nCOVID-19, tiene m\u00faltiples \nvariantes que circulan en los \nEE. UU. y globalmente durante \nesta pandemia. Hasta que no \ntengamos m\u00e1s datos sobre la \ndurabilidad y eficacia de las \nvacunas contra las variantes \nvamos a tener que continuar \nhaciendo lo que estamos \nhaciendo ahora. \nLas personas vacunadas deben \nseguir pr\u00e1cticas seguras, \npero pueden sentir cierta \ntranquilidad. Para aquellos que \na\u00fan no est\u00e1n vacunados, no \nretrase el obtener la vacuna \nque est\u00e9 disponible para usted.Alimentos y Medicamentos de \nestados Unidos (FDA, por sus \nsiglas ingl\u00e9s), ofrecer\u00e1n una \nprotecci\u00f3n adecuada contra \nestas nuevas variantes? Los \nexpertos en enfermedades \ninfecciosas del Mount Sinai \nresponden a estas importantes \npreguntas.\nJudith A. Aberg, MD, Decana \nde Operaciones del Sistema \nde Ciencias Cl\u00ednicas y Jefa de \nla Divisi\u00f3n de Enfermedades \nInfecciosas en la Escuela de \nMedicina Icahn en Mount Sinai, \ndirige las iniciativas sobre el de \ntratamiento covid-19 del Sistema \nde Salud de Mount Sinai y los \nesfuerzos de ensayo cl\u00ednico de \nvacunas. Dana Mazo, MD, MSc, \nProfesora Asistente de Medicina \n(Enfermedades Infecciosas) en \nla Escuela de Medicina Icahn en \nMount Sinai y Epidemi\u00f3loga de \nMount Sinai Queens, tambi\u00e9n es la investigadora principal \nde la unidad de ensayos \ncl\u00ednicos COVID-19 de Mount \nSinai Queens, que es un lugar \nde ensayo de vacunas J&J \nCOVID-19.\nP: \u00bfLas vacunas de Moderna \ny Pfizer nos protegen de las \nnuevas variantes?\nR: Al momento, nadie tiene \ndatos suficientes para darnos \nuna respuesta definitiva. \nTenemos indicios tanto de \nModerna como de Pfizer de \nque sus vacunas producen \nsuficientes anticuerpos eficaces \npara superar las variantes, \npero las personas todav\u00eda \npueden enfermarse levemente \ncon las variantes, aunque no \ngravemente. \nPfizer y Moderna anunciaron \nque podr\u00eda ser necesaria una \ntercera dosis de refuerzo \n Nuestra Comunidad\nServicios de Salud de Mount Sinai\nABRIL 2021\nMount Sinai Medical Center  |  Brand Guidelines  3Color is the primary visual device we \nuse to build consistent recognition of \nour brand. \nColor applications\nThe preferred version is our four-color \nlogo on a white background. The logo \nmay NOT appear on dark-colored \nbackgrounds. Please see the color \nbackgrounds page for more details.\nOne color applications\nThe logo may also be reproduced in \nsolid black on white.\nPantone\u00ae  \nProcess  \nCyan \nC  100   \nM 0   \nY  0   \nK 0\nR 0   \nG 174  \nB 239Pantone\u00ae  \n233\nC 10  \nM 100   \nY 0   \nK 0\nR 216   \nG 11  \nB 140Pantone\u00ae  \nProcess  \n274\nC 100   \nM 100 \nY 0   \nK 28\nR 34   \nG 31  \nB 114Pantone\u00ae  \nProcess  \nBlack\nC 0   \nM 0   \nY 0   \nK 100\nR 0   \nG 0  \nB 0Logo color applications\n4 Color  logo on white \nPrimary color palette1 Color logo on white\nSISTEMA DE SERVICIOS DE SALUD DE MOUNT SINAI \u2022 ASUNTOS DE LA COMUNIDAD Y DEL GOBIERNO \u2022 ONE GUSTAVE L. LEVY PLACE, BOX 1037 NEW YORK, NY 10029 \u2022 LINDA.HACKETT@MOUNTSINAI.ORG \u2022 646-265-1754continuaci\u00f3n  \u203a P: \u00bfEst\u00e1 bien mezclar \nvacunas para la primera y \nsegunda dosis o tomar m\u00e1s \nde una vacuna?\nR: No mezcle vacunas. \nTermine dos dosis de la misma \nvacuna o tome la dosis \u00fanica  \nde J&J. No sabemos si la \nrespuesta de anticuerpos a \nuna vacuna perjudicar\u00e1 su \nrespuesta inmune a la otra \nvacuna. A pesar de que las \nvacunas Moderna y Pfizer se \nbasan en la misma tecnolog\u00eda \nde ARNM, siguen siendo \nvacunas diferentes.\nP: \u00bfQu\u00e9 tan efectiva es  \nla nueva vacuna de  \nJohnson & Johnson?\nR: En todas las regiones \nestudiadas, la vacuna fue \n85 por ciento eficaz para \nprevenir enfermedades graves. \nAdem\u00e1s, nadie que ha recibido \nla vacuna ha tenido que ser \nhospitalizado y no ha habido \nmuertes relacionadas con \nel COVID-19. En los Estados \nUnidos, la vacuna ha tenido \nuna eficacia del 72 por ciento \ncontra covid-19 moderado y \ngrave, lo cual es realmente \nimpresionante. Eso significa \nque las personas que recibieron \nla vacuna ten\u00edan un 72 por \nciento menos de probabilidades \nde contraen enfermedades \nmoderadas o graves.\nLa vacuna Moderna es 94 por \nciento eficaz para prevenir \ncovid-19 sintom\u00e1tico, y la \nvacuna Pfizer es 95 por \nciento eficaz. Los expertos \ndicen que las tres vacunas no \ndeben compararse bas\u00e1ndose \nsolo en los n\u00fameros porque \ntodas proporcionan una \nfuerte protecci\u00f3n contra las \nenfermedades graves.Mount Sinai Medical Center  |  Brand Guidelines  3Color is the primary visual device we \nuse to build consistent recognition of \nour brand. \nColor applications\nThe preferred version is our four-color \nlogo on a white background. The logo \nmay NOT appear on dark-colored \nbackgrounds. Please see the color \nbackgrounds page for more details.\nOne color applications\nThe logo may also be reproduced in \nsolid black on white.\nPantone\u00ae  \nProcess  \nCyan \nC  100   \nM 0   \nY  0   \nK 0\nR 0   \nG 174  \nB 239Pantone\u00ae  \n233\nC 10  \nM 100   \nY 0   \nK 0\nR 216   \nG 11  \nB 140Pantone\u00ae  \nProcess  \n274\nC 100   \nM 100 \nY 0   \nK 28\nR 34   \nG 31  \nB 114Pantone\u00ae  \nProcess  \nBlack\nC 0   \nM 0   \nY 0   \nK 100\nR 0   \nG 0  \nB 0Logo color applications\n4 Color  logo on white \nPrimary color palette1 Color logo on white\ny consinti\u00f3 en participar \nsabiendo que recibir\u00edan una \ninyecci\u00f3n de placebo (agua \nsalada) o la vacuna J&J. A los \nparticipantes se les pregunt\u00f3 \ndos veces por semana si ten\u00edan \ns\u00edntomas, y si alguien report\u00f3 \ns\u00edntomas, se les hizo la prueba \npara ver si ten\u00edan COVID-19. \nP: \u00bfCu\u00e1l es su consejo para \nlas personas que han sido \ntotalmente vacunadas?\nR: Estas vacunas son una \nparte muy importante en \nnuestra caja de herramientas \nde prevenci\u00f3n. No podemos \nconfiar en una sola cosa. \nNo queremos establecer \nexpectativas de que no va \na contraer COVID-19, pero \nlas vacunas disminuyen sus \nposibilidades de enfermarse \no ser hospitalizado. As\u00ed que \nhasta que el virus est\u00e9 bajo \nun mejor control y no veamos \nuna tasa de incidencia tan alta, \ndebemos tener cuidado usando \nuna m\u00e1scara y continuando el \ndistanciamiento social.R: Cada una de las vacunas \ntiene pros y contras. El hecho \nde que la vacuna J&J sea una \nsola dosis es un beneficio real \nporque permite a m\u00e1s personas \nobtener protecci\u00f3n completa. \nEsta vacuna tambi\u00e9n es \nmucho m\u00e1s f\u00e1cil de almacenar \ny transportar. Algunas de \nlas otras vacunas requieren \nalmacenaje en un congelador \nultra fr\u00edo, lo cual no es posible \nen muchos lugares. \nCon la vacuna monodosis \nJ&J, tambi\u00e9n puede tener \nun menor riesgo de efectos \nsecundarios, en comparaci\u00f3n \ncon dos dosis que presentan \ndos oportunidades de efectos \nsecundarios. A partir de los \ndatos ya publicados, la vacuna \nJ&J parece muy bien tolerada. \nS\u00f3lo el 9 por ciento de las \npersonas reportaron fiebre \ndespu\u00e9s de la vacunaci\u00f3n y \nel 0,2 por ciento reportaron \nfiebres lo suficientemente malas \ncomo para interferir con las \nactividades diarias.\nP: \u00bfImporta qu\u00e9 vacuna \nrecibo?\nR: Obtenga la primera \nvacuna que se le ofrezca. \nTodas las vacunas ofrecen una \nbuena protecci\u00f3n contra la \nenfermedad grave de COVID-19, \nla hospitalizaci\u00f3n y la muerte. \nP: Estuvo usted involucrado \nen el ensayo cl\u00ednico \u00bfQu\u00e9 \nhizo Mount Sinai y por qu\u00e9 \nes tan importante?\nR: En Mount Sinai Brooklyn y \nMount Sinai Queens reclutamos \na miembros de nuestros \nvecindarios m\u00e1s diversos que \nestuvieron interesados en \nparticipar en un ensayo de  \nuna vacuna en investigaci\u00f3n  P: Algunos informes dicen \nque la vacuna de Johnson \n& Johnson es menos eficaz \nque otros. \u00bfEs eso cierto, y \neso es importante? \nR: Esta es una pregunta \nimportante. Una de las \ndiferencias con la vacuna \nJ&J es que el ensayo es m\u00e1s \nreciente y los datos publicados \nson del invierno del 2020. \nEn ese momento est\u00e1bamos \nviendo m\u00e1s casos de COVID-19 \ny nuevas variantes. Mirando \na otros pa\u00edses, la vacuna J&J \ntuvo una menor eficacia en \nAm\u00e9rica del Sur, 66 por ciento \ny Sud\u00e1frica, un 57 por ciento, \ny la eficacia general en todo el \nmundo fue un 66 por ciento.\nEl ensayo realizado en ocho \npa\u00edses en tres continentes \nincluye una poblaci\u00f3n diversa \ny amplia, incluyendo el 34 por \nciento de los participantes \nmayores de 60 a\u00f1os. El estudio \ninscribi\u00f3 a 44 por ciento de los \nparticipantes en los Estados \nUnidos: el 74 por ciento de \nlos participantes en el ensayo \nidentificados como blancos/\ncauc\u00e1sicos; 15 por ciento \nhispano y/o latino, 13 por ciento \ncomo negro/afroamericano,  \n6 por ciento asi\u00e1tico y 1 por \nciento nativo americano.\nOtro aspecto clave de la vacuna \nJ&J es que es una sola dosis. \nOtras vacunas han publicado \ndatos de mayor eficacia en \nun 90 por ciento o m\u00e1s, pero \ndespu\u00e9s de dos dosis. Este es \nun gran beneficio y tiene el \npotencial de ser un verdadero \ncambiador de juego en nuestra \nlucha contra la pandemia.\nP: \u00bfC\u00f3mo se compara \nesta vacuna a las otras dos \nvacunas? \u00bfEs mejor?Obtenga la primera vacuna que se le ofrezca. \nT odas las vacunas ofrecen una buena protecci\u00f3n \ncontra enfermedades graves de COVID-19, \nhospitalizaciones y muertes.\u203a \u203a\nSISTEMA DE SERVICIOS DE SALUD DE MOUNT SINAI \u2022 ASUNTOS DE LA COMUNIDAD Y DEL GOBIERNO \u2022 ONE GUSTAVE L. LEVY PLACE, BOX 1037 NEW YORK, NY 10029 \u2022 LINDA.HACKETT@MOUNTSINAI.ORG \u2022 646-265-1754Obtenga la \ninformaci\u00f3n m\u00e1s \nreciente sobre \nvacunaci\u00f3n  \nCOVID-19 de  \nMount Sinai\nVisite www.mountsinai.\norg/about/covid19/\nvaccine-information para  \nobtener la informaci\u00f3n  \nm\u00e1s reciente sobre  \nla disponibilidad, el uso,  \nla eficacia, y el tiempo  \nde vacunar. continuaci\u00f3n \n ABRIL 2021\nMount Sinai Medical Center  |  Brand Guidelines  3Color is the primary visual device we \nuse to build consistent recognition of \nour brand. \nColor applications\nThe preferred version is our four-color \nlogo on a white background. The logo \nmay NOT appear on dark-colored \nbackgrounds. Please see the color \nbackgrounds page for more details.\nOne color applications\nThe logo may also be reproduced in \nsolid black on white.\nPantone\u00ae  \nProcess  \nCyan \nC  100   \nM 0   \nY  0   \nK 0\nR 0   \nG 174  \nB 239Pantone\u00ae  \n233\nC 10  \nM 100   \nY 0   \nK 0\nR 216   \nG 11  \nB 140Pantone\u00ae  \nProcess  \n274\nC 100   \nM 100 \nY 0   \nK 28\nR 34   \nG 31  \nB 114Pantone\u00ae  \nProcess  \nBlack\nC 0   \nM 0   \nY 0   \nK 100\nR 0   \nG 0  \nB 0Logo color applications\n4 Color  logo on white \nPrimary color palette1 Color logo on white\nMartes, 6 & 20 de abril \n4 \u2013 5 pm\nCLASES DE DIABETES EN MOUNT SINAI\nEstas sesiones se van a alternar entre la Educaci\u00f3n \nsobre la Diabetes y el Grupo de Acci\u00f3n contra \nla Diabetes. Usted no tiene que asistir a todas \nlas clases, sin embargo, estar\u00e1 mejor informado \nsi participa en todas las sesiones del grupo. \nLas clases son presentadas por un educador \ncertificado en diabetes.\nConectar a la reuni\u00f3n ZOOM:\nPara m\u00e1s informaci\u00f3n y RSVP, comun\u00edquese con \nCamilla Levister al Camilla.Levister@mssm.edu .\nAUSPICIADO POR:  Mount Sinai Diabetes Center Jueves, 8, 15, 22 & 29 de abril\n11 am \u2013 mediod\u00eda\nDE MUJER A MUJER: GRUPO DE CANCER \nGINECOL\u00d3GICO \nConozca a otras mujeres que han sido diagnosticadas \ncon esta enfermedad que cambia la vida, con la \noportunidad de poder compartir su historia. El \nobjetivo es disminuir el aislamiento, compartir \nrecursos, ayudarle a sentirse empoderada, y ayudarle \na aprender maneras de hacer frente a los altibajos que \ntrae este diagn\u00f3stico. Nos acompa\u00f1ar\u00e1n los ponentes \ninvitados que son especialistas en sus campos.\nConectar a la reuni\u00f3n ZOOM: \nhttp://bit.ly/3sI7bhY\nID de reuni\u00f3n:  841 7354 5693 \nLlame al:  929-205-6099\nID de reuni\u00f3n:  84173545693#\nAUSPICIADO POR:  Cancer Supportive Services\nLunes, 12 & 26 de abril \n1 \u2013 2 pm\nGRUPO DE APOYO PARA PACIENTES  \nDE RADIOTERAPIA\nEste es un espacio para las personas que han \nrecibido o est\u00e1n recibiendo tratamientos de \nradiaci\u00f3n actualmente.\nPara obtener m\u00e1s informaci\u00f3n, o con RSVP, \ncomun\u00edquese con Emily Szafara al emily.szafara  \n@mountsinai.org  o llame al 212-523-7541, o a  \nEric White en eric.white@mountsinai.org   \no llame al 212-844-6072.\nConectar a la reuni\u00f3n ZOOM: \nhttps://bit.ly/37OCzo0 \nID de reuni\u00f3n:  320 489 3433\nLlame al:  1-646-876-9923\nAUSPICIADO POR:  Cancer Supportive Services Martes, 13 de abril \nMediod\u00eda \u2013 1 pm\nDE MUJER A MUJER: VIVIENDO CON  \nCANCER GYNECOLOGICO RECURRENTE \nEste grupo es para sobrevivientes de c\u00e1ncer \nginecol\u00f3gico que han experimentado una \nrecurrencia. Obtenga apoyo, aprenda de los \ndem\u00e1s y comparta recursos con aquellos que  \nse han enfrentado al c\u00e1ncer por segunda vez.\nConectar a la reuni\u00f3n ZOOM: \nhttp://bit.ly/3b7HgdK\nID de reuni\u00f3n:  827 5694 9116 \nLlame al:  929-205-6099\nID de reuni\u00f3n: 82756949116#\nAUSPICIADO POR: Cancer Supportive Services El sistema de salud Mount Sinai \ncontinuar\u00e1 ofreciendo eventos \nvirtuales  presentados de forma  \nremota y le permitir\u00e1n conectarse en \nl\u00ednea con un tel\u00e9fono, computadora \nport\u00e1til, de escritorio o tableta. Por \nfavor, utilice los enlaces, n\u00fameros de \nacceso telef\u00f3nico, y el ID de reuni\u00f3n  \na continuaci\u00f3n para unirse a nosotros.\nABC\u2019s de lo  \nensayos cl\u00ednicos de c\u00e1ncer\nC\u00d3MO PUEDEN A YUDARLE\nSe requiere matr\u00edcula.\nConectar a la reuni\u00f3n ZOOM: \nPara obtener informaci\u00f3n de ZOOM y \nRSVP, env\u00ede correo electr\u00f3nico cssevents@\nmountsinai.org  o llame al 212-523-7541.\nAUSPICIADO POR: Cancer Supportive ServicesT aller en espa\u00f1ol\nMi\u00e9rcoles, 21 de abril  \nmediod\u00eda \u2013 1 pm\nPanelistas:\nNicholas Rohs, MD, Profesor Asistente de \nMedicina (Hematolog\u00eda y Oncolog\u00eda M\u00e9dica)\nIvonne Pereira, NP, Mount Sinai West\nMaria T. Estrella, Co-Directora de LatinaSHARE\nModeradora:\nAlyssa Freeman, LMSW\nT aller chino/mandar\u00edn\nViernes, 23 de abril \n11 am \u2013 mediod\u00eda\nPanelistas:\nTheresa Shao, MD, Profesora Asistente de \nMedicina (Hematolog\u00eda y Oncolog\u00eda M\u00e9dica)\nHing Lin (Helen) Sit, LCSW, Gerente de \nChinatown NORC, Visiting Nurse Service  \nof New York\nModeradora:\nMi (Emma) Zhou, LCSW, Supervisora de \nTrabajo Social\nT aller en ingl\u00e9s\nJueves, 29 de abril  \nmediod\u00eda \u2013 1 pm\nPanelistas:\nStephanie Blank, MD, Directora de Ginecolog\u00eda \nOncol\u00f3gica, de Mount Sinai Health System\nDana Dornsife, fundadora y directora \nejecutiva de Lazarex Cancer Foundation\nModeradora:\nEmily Szafara, becaria en Trabajo Social Eventos virtuales  de la comunidad\nServicios de Salud de Mount Sinai\nSISTEMA DE SERVICIOS DE SALUD DE MOUNT SINAI \u2022 ASUNTOS DE LA COMUNIDAD Y DEL GOBIERNO \u2022 ONE GUSTAVE L. LEVY PLACE, BOX 1037 NEW YORK, NY 10029 \u2022 LINDA.HACKETT@MOUNTSINAI.ORG \u2022 646-265-1754", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}